Autolus enters 10-year lentiviral vector supply deal with AGC Biologics

Autolus Therapeutics plc

Master Service Agreement with AGC Biologics for lentiviral vector, critical for CAR-T production.
Minimum purchase: 14 batches in first 2 years; EUR 25 million over subsequent 5 years.
AGC granted first right to negotiate manufacturing of obe-cel (obecabtagene autoleucel).
10-year fixed term, non-exclusive; Autolus can terminate with certain fees, either party for default.
Agreement replaces prior arrangement; individual work orders govern specific projects.

item 1.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.